Sylphar confirms its buy & build strategy by acquiring 2 market leading brands in the antiperspirant business, Axitrans and Axideo
Brussels, 30 September 2019 – Sylphar, the fast-growing OTC company which teamed-up with Vendis Capital in May 2017 and acquired Pro Teeth Whitening and Nutravita in September 2018 , builds on its future ambition to become one of the leading branded and omni-channel European player in the consumer healthcare space, by acquiring Axitrans and Axideo, 2 leading brands in the antiperspirant business.
In 2008, Sylphar was founded by Robin List, as a spin-off from a publicly listed dental company. The company offers teeth whitening products under the leading brand iWhite, an innovative range of solutions for specific skin conditions under the Remescar brand, and oral therapeutics under the Herpatch (cold sores and ulcers) and Shur (bad breath) brands. Sylphar focuses on developing and marketing innovative products, whose production is outsourced and that are sold to the market through local distribution partners.
As from the start, Sylphar immediately experienced a year on year double digit growth through continuous innovation and geographic expansion. In 2017, Robin List teamed up with Vendis Capital to further develop Sylphar, with the ambition to build a portfolio of strategic niche brands with the ambition to obtain a leading position in their respective categories and geographies, be it organically or through acquisitions. In July 2018, Sylphar partnered with the founders of Pro Teeth Whitening and Nutravita, two leading digital brands respectively active in teeth whitening and supplements.
On September 17, 2019, the Belgian market leading brands Axitrans and Axideo were acquired by Sylphar, from the Vésale Pharmaceutical portfolio. Both Axitrans and Axideo have a good positioning in the antiperspirant niche market by offering a unique and therapeutic solution for people affected by hyperhidrosis, meaning the hyperactivity of sweat glands leading the body to produce a quantity of sweat greater than normal. Both brands benefit from a very strong brand recognition in Belgium.
Founder and CEO of Sylphar, Robin List comments: “. This acquisition is the second phase within our current buy & build strategy. Sylphar is continuously looking for new acquisitions within the healthcare & cosmetic business with a specific angle on niche and D2C brands. Axitrans and Axideo are a perfect add on to our brand portfolio. Our goal is to further strengthen the antiperspirant business by exploring the products full potential, and looking at geographic expansion.”